[
  {
    "start": "0",
    "end": "156000"
  },
  {
    "text": "Now I'd like to introduce Jan Pietzsch,\nwho is today's featured speaker. Dr. Pietzsch's professional and",
    "start": "10894",
    "end": "16257"
  },
  {
    "text": "academic work focuses on early\nstage technology assessment. And strategic decision support for\ninvestors, manufacturers and",
    "start": "16257",
    "end": "23165"
  },
  {
    "text": "research institutions. A primary emphasis is on evaluating the\nvalue proposition of new technologies, and",
    "start": "23166",
    "end": "28561"
  },
  {
    "text": "providing quantitative inputs into the\nselection of promising technology concepts and their targeted development.",
    "start": "28561",
    "end": "34995"
  },
  {
    "text": "These includes model based\nassessment of the clinical and health economic benefit from\nnew diagnostics and therapies.",
    "start": "34995",
    "end": "41783"
  },
  {
    "text": "He received his academic training at\nthe University of Karlsruhe in Germany. And also here at Stanford University\nwhere he completed his PhD.",
    "start": "41783",
    "end": "49184"
  },
  {
    "text": "Dr. Pietzsch is co-founder,\npresident, and CEO of WingTech Inc. That's the technology consulting\nfirm focused on health economic and",
    "start": "49184",
    "end": "56714"
  },
  {
    "text": "value assessment. Previously, he'd been a research\nfellow with the US FDA's Office of",
    "start": "56715",
    "end": "62323"
  },
  {
    "text": "Device Evaluation. Currently, he holds an appointment\nas Adjunct Professor of Management Science and\nEngineering at Stanford,",
    "start": "62323",
    "end": "68905"
  },
  {
    "text": "where he also serves as a director at\nthe Stanford Bio Center for Biodesign. The center is located here on campus\nnext to the medical school and",
    "start": "68905",
    "end": "76880"
  },
  {
    "text": "in the center of Silicon Valley,\nwhich seems fitting. And it's a leading program in\nmedical technology innovation.",
    "start": "76880",
    "end": "82940"
  },
  {
    "text": "It's vision is for a world where health technology innovators\nfrom around the globe have immersive,",
    "start": "82940",
    "end": "87957"
  },
  {
    "text": "collaborative, cutting edge training\nthat they require to thrive. And on that note,\nI'm going to hand over to Jan.",
    "start": "87957",
    "end": "95259"
  },
  {
    "text": ">> Thank you very much Marsha. Good morning everyone, it's a pleasure\nto see many of you registered here.",
    "start": "95259",
    "end": "101780"
  },
  {
    "text": "And it's also nice to see the interest in\nmedical technology because it's really, I think, one of the fields where you\ncan combine different interest and",
    "start": "101780",
    "end": "110040"
  },
  {
    "text": "area competencies and expertise and\nreally do something very meaningful by bringing technologies to patients\nthat really improve outcomes and",
    "start": "110040",
    "end": "118210"
  },
  {
    "text": "that also help to manage care, and\nprovide services in an appropriate manner.",
    "start": "118210",
    "end": "124659"
  },
  {
    "text": "Which is increasingly, as we see, important in healthcare\nsystems around the globe. We have two topics today that\nI'd like to discuss with you.",
    "start": "124660",
    "end": "132250"
  },
  {
    "text": "One is regulation of medical devices and\nthe second is economic value assessment.",
    "start": "132250",
    "end": "138178"
  },
  {
    "text": "They are really critical for\nthe successful bench to bedside innovation process of medical technology and\nso we'd like to highlight those.",
    "start": "138178",
    "end": "146130"
  },
  {
    "text": "In this webinar there is also a class we\nwill mention later that I'm teaching in the spring time for those of you\ninterested in taking the course online.",
    "start": "146130",
    "end": "152716"
  },
  {
    "start": "156000",
    "end": "514000"
  },
  {
    "text": "To set the stage let's look at\na couple of medical technologies. Starting from top left here, you see\na trans-catheter aortic heat valve,",
    "start": "156192",
    "end": "166310"
  },
  {
    "text": "or which is a new way to place and\nartificial heart valve. It replaces the surgical\nopen chest approach and",
    "start": "166310",
    "end": "174078"
  },
  {
    "text": "is one of the key cardiovascular\ninnovations of the last couple of years. It really facilitated treatment of\npatients that were previously not",
    "start": "174078",
    "end": "182165"
  },
  {
    "text": "candidates for surgery and\nneeded to be medically managed only. And also it's a candidate who\nare a technology that replaces over",
    "start": "182165",
    "end": "191060"
  },
  {
    "text": "time surgeries. So very high patient value device and\nwe get back to that later in a case study.",
    "start": "191060",
    "end": "197920"
  },
  {
    "text": "You see on the right, next to it,\ndeep brain simulation. Which is also an exciting neural\nsimulation technology that is used for",
    "start": "197920",
    "end": "206630"
  },
  {
    "text": "treatment of epilepsy, for example. For treatment of depression.",
    "start": "206630",
    "end": "211715"
  },
  {
    "text": "But also for\ntreatment of Parkinson's Disease. So a big patient impact and also,\none of the medical devices.",
    "start": "211715",
    "end": "218709"
  },
  {
    "text": "That they contribute to reduction and\nthe need for medication usage. So you see a direct link actually for",
    "start": "218710",
    "end": "225767"
  },
  {
    "text": "medical technology also can replace\npharmaceutical treatment regimens.",
    "start": "225768",
    "end": "231129"
  },
  {
    "text": "Next to it you see an advanced stem\ntherapy for cardiovascular applications. You see an imaging device for\nmammography or",
    "start": "231129",
    "end": "239413"
  },
  {
    "text": "breast cancer screening,\nwhich also has a very important field. I mean, all of imaging and diagnostics.",
    "start": "239413",
    "end": "246900"
  },
  {
    "text": "You see just next to it,\nfurther below, a treatment for obstructive sleep apnea,\nwhich is a big health concern.",
    "start": "246900",
    "end": "254599"
  },
  {
    "text": "I mean,\nobstructive sleep apnea is a condition, because it really elevates long-term\ncardiovascular and stroke risk.",
    "start": "254600",
    "end": "260590"
  },
  {
    "text": "And in patients who don't\ntolerate CPAP treatment which is a mask based treatment\nto treat sleep apnea.",
    "start": "260590",
    "end": "267309"
  },
  {
    "text": "A new device has been developed that\nagain uses neurostimulation technology to stimulate the tongue base at night and\nthereby keep the airway open.",
    "start": "267309",
    "end": "275790"
  },
  {
    "text": "Then you see a diagnostic device for\nglucose monitoring which you can",
    "start": "277620",
    "end": "282741"
  },
  {
    "text": "see over the counter or can purchase\nin any pharmacy in the United States,",
    "start": "282741",
    "end": "288213"
  },
  {
    "text": "certainly at the large need,\nor large number of users. But their continued advancements,\nalso with the connection to mobile health",
    "start": "288213",
    "end": "297520"
  },
  {
    "text": "technologies that really facilitate better\nmanagement of the condition of diabetes.",
    "start": "297520",
    "end": "303296"
  },
  {
    "text": "Then next it, to the left,\nyou see a new approach to actually diagnosis lung cancer and\nto avoid invasive procedures.",
    "start": "303296",
    "end": "312170"
  },
  {
    "text": "It's a genomic marker test. You see here a bronchoscopy\nbeing performed and a brush that is used to take a sample\nwhich is then analyzed in a lab.",
    "start": "312170",
    "end": "322920"
  },
  {
    "text": "To determine the risk or\nthe likelihood that the patient actually does have\na cancerous condition or a lesion.",
    "start": "322920",
    "end": "329960"
  },
  {
    "text": "And by using such new technology there is the opportunity to reduce\ninvasive surgical biopsy.",
    "start": "329960",
    "end": "338099"
  },
  {
    "text": "And you can imagine that that's really\na risk reduction for the patent and it's a benefit also for the healthcare system in terms of\navoiding costs of complex procedures.",
    "start": "338100",
    "end": "346680"
  },
  {
    "text": "Then a device that is a family of devices,\nartificial joints, you see the hip joint here excuse\nme the knee joint, roughly 700,000",
    "start": "347740",
    "end": "356632"
  },
  {
    "text": "total knee replacements are performed\nper year in the United States alone. And again, big impact on patient quality\nof life in patients with severe arthritis.",
    "start": "356632",
    "end": "368200"
  },
  {
    "text": "But also a big market for medical\ntechnology or orthopedic technologies. And then finally, technology that's\na high flow therapy respiratory support",
    "start": "368200",
    "end": "378361"
  },
  {
    "text": "systems that are gradually replacing\nmore invasive respiratory support,",
    "start": "378361",
    "end": "383686"
  },
  {
    "text": "mordalities, such as antiobasin\nother wise mask based treatments.",
    "start": "383686",
    "end": "389340"
  },
  {
    "text": "Again, I think all of these\ntechnologies and there are many, many more show you the wide\nvariety of technologies and",
    "start": "389340",
    "end": "394910"
  },
  {
    "text": "the wide variety of opportunities\nto really improve patient care and patient outcomes.",
    "start": "394910",
    "end": "403360"
  },
  {
    "text": "Now for all of these technologies,\nif you're thinking of innovations in those spaces, right,\nwe need to think about demonstrating",
    "start": "403360",
    "end": "411979"
  },
  {
    "text": "the value of these technologies to\nthe patients or at least developing and understanding, right, how meaningful\na technology is to patients.",
    "start": "411980",
    "end": "419810"
  },
  {
    "text": "We also need to think about\nthe questions of safety and effectiveness of these technologies.",
    "start": "419810",
    "end": "424100"
  },
  {
    "text": "And the leading question, our lead\nquestion really is what constitutes safety",
    "start": "425380",
    "end": "430400"
  },
  {
    "text": "of a medical technology? What does it take to demonstrate\nsafety and effectiveness?",
    "start": "430400",
    "end": "434530"
  },
  {
    "text": "Next do we need to worry or\nthink about the target population. If there's a very narrow defined\npopulation that could benefit",
    "start": "436200",
    "end": "444468"
  },
  {
    "text": "from the therapy or the technology,\nor is it a larger target population. Thinking of the knee replacement,\n$700,000 per year number of devices.",
    "start": "444468",
    "end": "453860"
  },
  {
    "text": "That's a very different to\nsome other technology areas. So we need to appreciate and\ndefine the target population,",
    "start": "453860",
    "end": "459929"
  },
  {
    "text": "because it also has an affect\non the safety profile and on the effectiveness profile and\nwe'll discuss that in a minute.",
    "start": "459929",
    "end": "467138"
  },
  {
    "text": "And then finally,\nis this technology of value, right? Should it be paid for, and if so,\nWhat amount would be appropriate for",
    "start": "467138",
    "end": "475355"
  },
  {
    "text": "healthcare systems. And we also need to keep in mind that\nthis value question really is stakeholder",
    "start": "475355",
    "end": "480526"
  },
  {
    "text": "specific, and it's country specific. So a technology that might be\nof value in the United States. Healthcare system might not be of value\nin other healthcare systems like the UK,",
    "start": "480526",
    "end": "490883"
  },
  {
    "text": "France, Spain, or Japan. And the reason is that we not only\nmight have some slight variations",
    "start": "490883",
    "end": "497460"
  },
  {
    "text": "in the underlying clinical profile. But we have very different\nimplementations of healthcare systems and",
    "start": "497460",
    "end": "503007"
  },
  {
    "text": "also different cost structures and\ncost profiles. And so you see that all of these questions\nreally directly relate to the fields of",
    "start": "503007",
    "end": "509792"
  },
  {
    "text": "regulation and\nhealth economics that we discussed today. And a point here that we should\nmention specifically here is that very",
    "start": "509792",
    "end": "519412"
  },
  {
    "start": "514000",
    "end": "625000"
  },
  {
    "text": "different from other industries\nlike the automotive industry or many consumer electronics fields.",
    "start": "519412",
    "end": "526603"
  },
  {
    "text": "Commercial success and bringing\na therapy really to the patient for commercial use means that we need\nto rely on approval by regulatory",
    "start": "526603",
    "end": "535756"
  },
  {
    "text": "authorities in the United States\nthe Food and Drug Administration. And we also need to obtain reasonable\npositive reimbursement that",
    "start": "535756",
    "end": "545332"
  },
  {
    "text": "actually allows us to\na business in the end. So without those third party\nconsiderations or approval by third",
    "start": "545332",
    "end": "554433"
  },
  {
    "text": "parties, there's no way to have a\nsuccessful translation from development or",
    "start": "554433",
    "end": "560834"
  },
  {
    "text": "R&D to the clinical use and\nthe patient benefit. So that means we need to understand very\nthoroughly the requirements of regulatory",
    "start": "560834",
    "end": "569803"
  },
  {
    "text": "approval, and of reimbursement\napproval and value assessment. And there's a direct link as you probably\nappreciate between the requirements and",
    "start": "569804",
    "end": "579762"
  },
  {
    "text": "the commercialization risks and\nrewards of the time to market, imagine for example, a required two year followup\nstudy as opposed to six month followup.",
    "start": "579762",
    "end": "589239"
  },
  {
    "text": "That very much affects\nyour time to market and it also affects the costs of\ndevelopment and clinical testing.",
    "start": "589239",
    "end": "596269"
  },
  {
    "text": "And that leads us directly also\nto the funding requirement, when you think of raising funds for\na new concept or new technology.",
    "start": "596270",
    "end": "603968"
  },
  {
    "text": "The questions of what\naspects of regulation and reimbursement really drive heavily\nthe funding requirement question as well.",
    "start": "603968",
    "end": "611870"
  },
  {
    "text": "And there's an increasing importance\nglobally to demonstrate value in a changing healthcare environment.",
    "start": "613570",
    "end": "620130"
  },
  {
    "text": "So let's talk about regulation. Couple of years ago, we did a study at\nStanford Biodesign where we outlined",
    "start": "622437",
    "end": "630407"
  },
  {
    "start": "625000",
    "end": "693000"
  },
  {
    "text": "the medical development process from the\nvery early stage of need identification,",
    "start": "630407",
    "end": "635635"
  },
  {
    "text": "all the way through post market and\nyou see, key activities listed here. You see also decision gates along the way.",
    "start": "635635",
    "end": "643509"
  },
  {
    "text": "And what was really striking, is that\nmore than half of the activities and the decisions are governed by regulatory\nand reimbursement requirements.",
    "start": "643510",
    "end": "651850"
  },
  {
    "text": "Most of them actually\nregulatory requirements. Second point I'd like to make here is\nthat regulation not only relates to",
    "start": "651850",
    "end": "659069"
  },
  {
    "text": "the approval of medical technologies or\nthe pre market review, as it's called. But also to the full life\ncycle of a medical device.",
    "start": "659069",
    "end": "668207"
  },
  {
    "text": "So all aspects of surveillance in\nthe field managing feedback that you received from patients and\nproviders about issues with the device.",
    "start": "668207",
    "end": "678519"
  },
  {
    "text": "Manufacturing, productions,\nall of those aspects are regulated and governed by regulations. And so In order to successfully manage\na business, you need to be aware",
    "start": "678520",
    "end": "688419"
  },
  {
    "text": "of those requirements, and\nimplement procedures accordingly. Two important definitions that govern\nFDA's work when evaluating technology,",
    "start": "688419",
    "end": "699277"
  },
  {
    "start": "693000",
    "end": "708000"
  },
  {
    "text": "you see the legal definitions from\nthe Code of Federal Regulations for",
    "start": "699278",
    "end": "704450"
  },
  {
    "text": "Safety and for Effectiveness. And let me just read them to you. There's reasonable assurance that a device\nis safe when it can be determined based on",
    "start": "704450",
    "end": "713333"
  },
  {
    "start": "708000",
    "end": "1153000"
  },
  {
    "text": "valid scientific evidence\nthat the probable benefits to health from use of the device for\nits intended uses.",
    "start": "713333",
    "end": "718885"
  },
  {
    "text": "And conditions of use when accompanied\nby adequate directions and warnings against unsafe use,\noutweigh the probable risks.",
    "start": "718885",
    "end": "726140"
  },
  {
    "text": "Again, in the definition of safety\nyou see this balance of benefits and risks, or that the benefits\nneed to outweigh the risks.",
    "start": "726140",
    "end": "733610"
  },
  {
    "text": "You also see a couple of\nimportant definitions. One is the question of what\nconstitutes valid scientific evidence.",
    "start": "734940",
    "end": "742430"
  },
  {
    "text": "Is it a randomized control? Try it, for example,\nwith the highest level of evidence.",
    "start": "742430",
    "end": "748700"
  },
  {
    "text": "Or it is sufficient,\nfor some technologies, to use less comprehensive data to use,\nfor example a single arm study,",
    "start": "748700",
    "end": "754990"
  },
  {
    "text": "and compare the results to previously\npublished results from another technology.",
    "start": "754990",
    "end": "759440"
  },
  {
    "text": "So this is a very relevant and\nkey question. And also is actually one of the drivers",
    "start": "760470",
    "end": "766620"
  },
  {
    "text": "in the implementation of\nthe regulatory process. You may have heard about\nthe regulatory pendulum.",
    "start": "766620",
    "end": "772816"
  },
  {
    "text": "That there were differences between how\nto administrations actually enforced regulation. And implemented regulation as one of\nthe key drivers here is the question,",
    "start": "772816",
    "end": "781881"
  },
  {
    "text": "how much evidence is needed and what is\nconsidered to be valid or valid enough?",
    "start": "781881",
    "end": "786399"
  },
  {
    "text": "Another definition is the intended use. You cannot get clearance for a technology.",
    "start": "787660",
    "end": "793930"
  },
  {
    "text": "For use in any patient,\nit's always for one specific or several specific indications per\nuser intended to do with this.",
    "start": "793930",
    "end": "801110"
  },
  {
    "text": "And you also need to be\ncareful in describing and specifying what is the condition of use. Is it in an inpatient setting and an\noutpatient setting, who is performing or",
    "start": "802140",
    "end": "810923"
  },
  {
    "text": "using the device,\nall of those are relevant questions for the regulatory review process.",
    "start": "810924",
    "end": "816490"
  },
  {
    "text": "Labeling is part of that,\nas well as the instructions for use.",
    "start": "816490",
    "end": "820520"
  },
  {
    "text": "Effectiveness, looking further below, there is reasonable assurance that\na device is defective when it can be",
    "start": "821520",
    "end": "827771"
  },
  {
    "text": "determined based upon again\nvalid scientific evidence. At any significant portion of the target\npopulation the use of the device for",
    "start": "827771",
    "end": "835159"
  },
  {
    "text": "it's intended use and conditions of use\nwhen adequately to the warnings against unsafe use they provide\nclinically significant results.",
    "start": "835159",
    "end": "843250"
  },
  {
    "text": "Again definitions of valid\nscientific evidence. Also definitions for\nintended use in a given population and",
    "start": "845230",
    "end": "854933"
  },
  {
    "text": "also the definition of clinically\nsignificant results that means the FDA.",
    "start": "854933",
    "end": "861810"
  },
  {
    "text": "For example, the European regulatory\nrequirement FDA really evaluates the benefit to the patient in terms of\noutcome, in terms of effectiveness.",
    "start": "861810",
    "end": "870529"
  },
  {
    "text": "It's not sufficient to agree that\na technology's safe enough, but",
    "start": "870530",
    "end": "875795"
  },
  {
    "text": "it really needs to demonstrate\na clinically significant improvement.",
    "start": "875795",
    "end": "881347"
  },
  {
    "text": "In Europe, the focus with the labeling,\nfor those interested and familiar with the European system Is\nto evaluate safety, and performance.",
    "start": "881348",
    "end": "891235"
  },
  {
    "text": "And performance means,\nnot the clinical performance, but that revise does what it's intended to do,\nbut there's no long term",
    "start": "891235",
    "end": "899366"
  },
  {
    "text": "evaluation of outcomes as part\nof the regulatory process.",
    "start": "899366",
    "end": "903110"
  },
  {
    "text": "How is regulation implemented\nin the United States? When Congress enacted medical\ndevice regulation in 1976,",
    "start": "905710",
    "end": "912770"
  },
  {
    "text": "following pharmaceutical regulation,\nwhich was in place since the 1930s, with the Food, Drug, and Cosmetics Act.",
    "start": "912770",
    "end": "919050"
  },
  {
    "text": "Congress determined that for medical\ndevices and, again, differential pharma, it does make sense to consider\nthe risk level of a device.",
    "start": "920250",
    "end": "926410"
  },
  {
    "text": "Because, you can imagine,\nmedical devices like syringes. And you see the photo here on the right,\nhave a much different",
    "start": "926410",
    "end": "934521"
  },
  {
    "text": "risk profile than a intracardiac stint or\ncatheter. And so the three risks, one, two,\nthree, increasing in risk level.",
    "start": "934521",
    "end": "945019"
  },
  {
    "text": "And the review requirement are different. There are exempt devices that really\nrequire only the registration",
    "start": "945020",
    "end": "953818"
  },
  {
    "text": "of the manufacturer but no submission\nof clinical or other Test data.",
    "start": "953818",
    "end": "960740"
  },
  {
    "text": "Then there's the so-called 510(k) process. The definition actually goes back to\nthe Court of Federal Regulation section.",
    "start": "960740",
    "end": "967500"
  },
  {
    "text": "It's the typical process for\nClass Two devices, and it requires demonstration of substantial equivalent\nto one or several predicate devices.",
    "start": "967500",
    "end": "975670"
  },
  {
    "text": "So as long as you can show that your\ntechnology performs similarly to an existing technology, or\nuses technology components that",
    "start": "975670",
    "end": "983966"
  },
  {
    "text": "were previously cleared\nthrough the 510(k) process, you can demonstrate would be upper\nreview by FDA, you can demonstrate if",
    "start": "983966",
    "end": "992492"
  },
  {
    "text": "you're successful that the technology's\nsubstantially equivalent. And therefore should be cleared\nto market via the 510(k) process.",
    "start": "992492",
    "end": "1001299"
  },
  {
    "text": "Then there's pre-market approval or PMA,\nwhich is the highest regulatory process.",
    "start": "1001299",
    "end": "1006672"
  },
  {
    "text": "It's very much comparable to\nthe new drug application process.",
    "start": "1006672",
    "end": "1012175"
  },
  {
    "text": "And medical devices always\nrequire a trial-based evaluation, typically with several\nphases of clinical trials.",
    "start": "1012175",
    "end": "1018130"
  },
  {
    "text": "In addition to pre-market evaluation and\nclearance as I mentioned earlier, there are regulations governing\nmanufacturing and other aspects,",
    "start": "1020404",
    "end": "1028194"
  },
  {
    "text": "quality system regulations, R&D processes\nmanufacturing, procurement distribution, product surveillance and\nmany other aspects.",
    "start": "1028195",
    "end": "1035701"
  },
  {
    "text": "FDA review was actually\na paper-based review, I mean even though lot of these\npapers are now electronic.",
    "start": "1039132",
    "end": "1047100"
  },
  {
    "text": "But it's not that FDA evaluates a device,\ntakes it apart and studies its risk profile.",
    "start": "1047100",
    "end": "1053639"
  },
  {
    "text": "Companies submit documentation of\ntests that were performed, and you see how comprehensive these dockets\nare, this is for a PMA-type device.",
    "start": "1053640",
    "end": "1063680"
  },
  {
    "text": "And what FDA receives and then needs\nto review within 180 days typically.",
    "start": "1063680",
    "end": "1068740"
  },
  {
    "text": "And you can imagine that\nthat's a tall order, and a very comprehensive task involving\nbiostatistics, engineering,",
    "start": "1068740",
    "end": "1076399"
  },
  {
    "text": "medical disciplines, and so on, and\nwe expert knowledge within the agency.",
    "start": "1076400",
    "end": "1080339"
  },
  {
    "text": "As mentioned earlier, the implementation of the regulatory\nreview process has changed over time.",
    "start": "1083103",
    "end": "1089687"
  },
  {
    "text": "This show is a shot comes from\nthe latest MDUFA report that FDA published just early this year.",
    "start": "1089687",
    "end": "1097390"
  },
  {
    "text": "And it shows the pre-market approval,\nagain the highest risk does divides approvals, and\nyou'll see in green the successful or",
    "start": "1097390",
    "end": "1105490"
  },
  {
    "text": "approved devices and\nhow that's changed over the years. And you can see, for example, with\nthe beginning of the Obama administration",
    "start": "1105490",
    "end": "1115170"
  },
  {
    "text": "in 2008 and 2009, the approval rates for\nPMAs really went down significantly.",
    "start": "1115170",
    "end": "1121430"
  },
  {
    "text": "And that was the results of stricter\nrequirements that the new administration or the new leadership at FDA\nimplemented at that time.",
    "start": "1121430",
    "end": "1129390"
  },
  {
    "text": "Since then it has dramatically\nincreased again, and FDA has been very successful actually\nin further improving its operations and",
    "start": "1129390",
    "end": "1137100"
  },
  {
    "text": "procedures, which is good news to\neveryone involved in the industry.",
    "start": "1137100",
    "end": "1141240"
  },
  {
    "text": "Now let's switch over to our second topic,\nhealth-economic value assessment,",
    "start": "1144296",
    "end": "1150284"
  },
  {
    "text": "to give you some background about\nthe environment that we all or anyone operating in the field\nof medical devices.",
    "start": "1150284",
    "end": "1158510"
  },
  {
    "start": "1153000",
    "end": "1259000"
  },
  {
    "text": "Now, in these two phase, you see for\nthe United States, again, the total federal spending is percent of\nthe Gross Domestic Product over the years.",
    "start": "1158510",
    "end": "1168820"
  },
  {
    "text": "And you can appreciate or see here in red,\nthe major head programs, that's Medicare",
    "start": "1168820",
    "end": "1174450"
  },
  {
    "text": "and Medicaid, primarily being the highest\nspending category of government spending.",
    "start": "1174450",
    "end": "1181240"
  },
  {
    "text": "Roughly 5% of the GDP and consider that this is only\nthe government part of health care.",
    "start": "1181240",
    "end": "1187090"
  },
  {
    "text": "When you add all of the private aspects,\nand commercial insurance aspects of health\ncare, you're currently looking at 18 or",
    "start": "1187090",
    "end": "1195320"
  },
  {
    "text": "19% of the the GDP being spent on\nhealth care in the United States, which is roughly double what\nother countries in Europe spend.",
    "start": "1195320",
    "end": "1202430"
  },
  {
    "text": "And it's not only in Europe, but\nespecially in the US it's a concern, especially when you look at\nthe projected future expenses,",
    "start": "1202430",
    "end": "1210600"
  },
  {
    "text": "which are driven among\nother factors by changes in the age groups, for example,\nof patients, demographic changes.",
    "start": "1210600",
    "end": "1219750"
  },
  {
    "text": "And you can also appreciate that's\njust occurred or what's proposed. If defense spending, which you see\nfurther down, is increased by $50 billion",
    "start": "1220760",
    "end": "1229610"
  },
  {
    "text": "from one year to the other at the expense\nof other government spending categories,",
    "start": "1229610",
    "end": "1234670"
  },
  {
    "text": "that there is even more pressure on\nspending on healthcare for example.",
    "start": "1234670",
    "end": "1240585"
  },
  {
    "text": "Right, and that means also,\nthere needs to be significant scrutiny, and funds should be spent\nwisely on technologies or",
    "start": "1240585",
    "end": "1248720"
  },
  {
    "text": "aspects of healthcare that really\nare meaningful and contribute value. And that's the environment we live in and",
    "start": "1248720",
    "end": "1254340"
  },
  {
    "text": "that we are increasingly\nfacing going forward.",
    "start": "1254340",
    "end": "1256390"
  },
  {
    "start": "1259000",
    "end": "1385000"
  },
  {
    "text": "Therefore, not only in\nthe United States but globally, any healthcare system,\nregardless of their ability to spend, and",
    "start": "1260966",
    "end": "1268810"
  },
  {
    "text": "the absolute amount of\nspending on health care. All health care systems face\nthe issue of improving or",
    "start": "1268810",
    "end": "1275630"
  },
  {
    "text": "the desire to further\nimprove patient outcomes, while also managing costs, controlling\ncosts, in some cases, reducing costs.",
    "start": "1275630",
    "end": "1282910"
  },
  {
    "text": "And so technology really can\ncontribute significantly to helping resolve these issues, right?",
    "start": "1282910",
    "end": "1288430"
  },
  {
    "text": "We just need to make sure that\nthe technology we're bringing forward really address one or\ntwo of these concerns.",
    "start": "1288430",
    "end": "1296849"
  },
  {
    "text": "Ideally both of them, right, in outcome improvement and\noverall same or reduced cost.",
    "start": "1297850",
    "end": "1302830"
  },
  {
    "text": "Now when we look further at value, we need to appreciate that there\nare different stakeholders involved.",
    "start": "1305545",
    "end": "1312010"
  },
  {
    "text": "It's not sufficient to only look\nat Medicare, for example, and show that Medicare expenses, even though\nthat's very important and relevant, right?",
    "start": "1312010",
    "end": "1319365"
  },
  {
    "text": "If Medicare expenses are reduced with\nthe introduction of a new technology,",
    "start": "1319365",
    "end": "1324476"
  },
  {
    "text": "it might be that it comes at increased\ncost, or lower revenue margins for the hospitals, right?",
    "start": "1324476",
    "end": "1330950"
  },
  {
    "text": "And so, from a hospital perspective,\nfrom a pure financial perspective, that would mean that it's not of\nvalue to adopt a new technology.",
    "start": "1330950",
    "end": "1338730"
  },
  {
    "text": "And so keeping in mind that\nthe argument driver should always be an improvement in patient outcomes,\nbut on the financial side, we need",
    "start": "1338730",
    "end": "1345410"
  },
  {
    "text": "to be aware of those ramifications, and\nbe aware of different stakeholders. We need to think about demonstrating\nincremental improvement,",
    "start": "1345410",
    "end": "1354013"
  },
  {
    "text": "compare the status quo. Which also means that\nwe need to identify and very carefully appreciate how\ntechnologies are currently, or",
    "start": "1354013",
    "end": "1362010"
  },
  {
    "text": "how patients treated with\nexisting technologies, right? And we need to identify\nthe incremental changes.",
    "start": "1362010",
    "end": "1368450"
  },
  {
    "text": "We need to have a focus on cost and\noutcome, demonstrate the long term perspective.",
    "start": "1368450",
    "end": "1373627"
  },
  {
    "text": "And consider not only the episode of care,\nbut also the longer term implications\nin terms of costs and outcomes",
    "start": "1373627",
    "end": "1380537"
  },
  {
    "start": "1385000",
    "end": "1640000"
  },
  {
    "text": "So from a patient perspective, again,\ngoing back to the clinical objectives of",
    "start": "1385602",
    "end": "1391404"
  },
  {
    "text": "any new technology, we need to be able\nto demonstrate either a reduction",
    "start": "1391404",
    "end": "1396608"
  },
  {
    "text": "mortality survival improvement, or\na reduction in patient morbidity,",
    "start": "1396608",
    "end": "1401901"
  },
  {
    "text": "or a improvement in patient\nrelated quality of life. In some technologies, actually,",
    "start": "1401901",
    "end": "1406950"
  },
  {
    "text": "we're able to address all of them,\nbut keep in mind that these are the three drivers really that\ndrive the value proposition to a patient.",
    "start": "1406950",
    "end": "1414240"
  },
  {
    "text": "And we need to be able to demonstrate\na viable economic profile, a therapy needs to be either cost-saving\nor cost-effective to be of value.",
    "start": "1415670",
    "end": "1424420"
  },
  {
    "text": "And that is measured through\nthe cost-effectiveness ratio, on the right-hand side you see a graph\nwhere you see at the zero point or",
    "start": "1424420",
    "end": "1431410"
  },
  {
    "text": "the cross of the axis,\nthe existing approach and technology, how a patient might be\ntreated and given an indication, and",
    "start": "1431410",
    "end": "1438279"
  },
  {
    "text": "we are looking at The difference in costs. There's our costs on the y axis. And the difference in outcomes or",
    "start": "1438280",
    "end": "1444520"
  },
  {
    "text": "effectiveness of measured in quality\nadjusted life here is to the right. And you can appreciate that\nthere might be technologies",
    "start": "1444520",
    "end": "1451169"
  },
  {
    "text": "that lead to better patient\noutcomes at higher overall costs. And up to a certain willingness to pay\nthreshold that is defined by individual",
    "start": "1451170",
    "end": "1459419"
  },
  {
    "text": "healthcare systems, the technology might\nbe considered to be of good value, to be cost effective.",
    "start": "1459420",
    "end": "1465450"
  },
  {
    "text": "And that means it should be adopted. There are also technologies\nthat hopefully in the future,",
    "start": "1465450",
    "end": "1471360"
  },
  {
    "text": "more technologies that\nimprove patient outcomes. But also reducing overall cost\nto the healthcare system, and",
    "start": "1471360",
    "end": "1477240"
  },
  {
    "text": "it would be in the quadrant\non the lower right. When we think of developing technology\nthat leads to higher costs, and",
    "start": "1477240",
    "end": "1485373"
  },
  {
    "text": "many, many, increased effectiveness that\nlie above the willingness to pay threshold here, then you can appreciate that they're\nnot considered to be of good value, and",
    "start": "1485373",
    "end": "1494730"
  },
  {
    "text": "would be very hard to actually get a\nsuccessful adoption of those technologies in the future.",
    "start": "1494730",
    "end": "1499861"
  },
  {
    "text": "So the implications continued here\nwe need to again, appreciate all of the requirements and how agencies like\nin the UK, the National Institute",
    "start": "1502265",
    "end": "1511813"
  },
  {
    "text": "of Clinical Excellence,\nhow they evaluate technologies and we need to collect data in a prospective\nway from the very early stage of",
    "start": "1511813",
    "end": "1520498"
  },
  {
    "text": "development all the way through clinical\nand be aware of those requirements.",
    "start": "1520498",
    "end": "1525690"
  },
  {
    "text": "Let me briefly go through a case study for\nTAVR, transcatheter aortic valve",
    "start": "1527940",
    "end": "1533629"
  },
  {
    "text": "replacement, remember that we looked at\nthis technology on the very first slide. And, I'd like to briefly discuss with\nyou the safety effectiveness and",
    "start": "1533630",
    "end": "1542226"
  },
  {
    "text": "value assessment,\nbased on this real world technology.",
    "start": "1542226",
    "end": "1545627"
  },
  {
    "text": "Brief background about the medical\ncondition aortic valve disease. The aortic valve is actually\nthe most important.",
    "start": "1550236",
    "end": "1557770"
  },
  {
    "text": "All of the heart valves are important,\nbut the most important valve or highest pressure valve, actually between\nthe left ventricle and the aorta and",
    "start": "1557770",
    "end": "1565460"
  },
  {
    "text": "the main body artery vasculature. And in many patients,",
    "start": "1565460",
    "end": "1571560"
  },
  {
    "text": "aortic stenosis in older ages leads\nto a narrowing of this valve.",
    "start": "1571560",
    "end": "1575730"
  },
  {
    "text": "In the old days and up to now, the main treatment approach was open\nheart surgery, which is the on top here.",
    "start": "1576780",
    "end": "1584950"
  },
  {
    "text": "Which requires a very invasive procedure,\nopen chest, and you can increase the.",
    "start": "1584950",
    "end": "1590519"
  },
  {
    "text": "Now what that means in terms of length of\nstay, in terms of quality of life impact, of the mortality impact in fact.",
    "start": "1590520",
    "end": "1596345"
  },
  {
    "text": "And transcatheter aortic valve replacement\nis a new technology that has been introduced over the last decade to average",
    "start": "1596345",
    "end": "1605000"
  },
  {
    "text": "patients that are not candidates for\nsurgery because they're too sick, too ill, and wouldn't survive or\npossibly survive surgery.",
    "start": "1605000",
    "end": "1612140"
  },
  {
    "text": "And increasingly, this approach is\nalso used to replace surgeries and",
    "start": "1613140",
    "end": "1618810"
  },
  {
    "text": "candidates that are at intermediate risk. And you can see on this image here on the\nright-hand side how the valve is actually",
    "start": "1618810",
    "end": "1626417"
  },
  {
    "text": "implanted through the catheter without\nopening the chest of the patient.",
    "start": "1626417",
    "end": "1631004"
  },
  {
    "text": "So now if we look through\nthe regulatory or the value lens again, it's starting with the question\nof general evaluation of TAVR,",
    "start": "1634716",
    "end": "1643841"
  },
  {
    "start": "1640000",
    "end": "1876000"
  },
  {
    "text": "we probably should compare this TAVR\napproach against surgical treatment,",
    "start": "1643841",
    "end": "1649283"
  },
  {
    "text": "in patients that are candidates for\nsurgery. In patients previously not candidates for\nsurgery, we need to compare",
    "start": "1649283",
    "end": "1657220"
  },
  {
    "text": "against the existing paradigm for these\npatients, which was medical management. So again it shows that we\nneed to carefully present and",
    "start": "1657220",
    "end": "1665940"
  },
  {
    "text": "understand what the patient\npopulation that we're looking at when evaluating the technology, and also\nwhat the current paradigm of treatment.",
    "start": "1665940",
    "end": "1672830"
  },
  {
    "text": "Because that drives our incremental\ndifferences in terms of patient outcome, and in terms of cost.",
    "start": "1672830",
    "end": "1677820"
  },
  {
    "text": "How should we evaluate the effectiveness? Well it's the long term survival that\nreally is the most meaningful factor here.",
    "start": "1679050",
    "end": "1688460"
  },
  {
    "text": "So we need to appreciate not\nonly the procedural success or maybe six month follow up outcome but\nideally the remaining lifetime of",
    "start": "1688460",
    "end": "1696640"
  },
  {
    "text": "the patient and how survival is\naffected by this new technology.",
    "start": "1696640",
    "end": "1701710"
  },
  {
    "text": "We also need to think about\nevents like strokes and heart attacks that might be affected\nby the use of the technology.",
    "start": "1701710",
    "end": "1709120"
  },
  {
    "text": "And to assess those outcomes, ideally,\nwe would want to see one year or two year outcomes from a trial\nto be able to evaluate that.",
    "start": "1710170",
    "end": "1717898"
  },
  {
    "text": "There are also factors like\nsix minute walk test and other approaches to evaluate\nthe functional ability of a patient.",
    "start": "1719850",
    "end": "1727881"
  },
  {
    "text": "All of those factors in sum\nreally drive effectiveness and do have an impact on the quality of\nthe That we're measuring and Analysis.",
    "start": "1727881",
    "end": "1738229"
  },
  {
    "text": "What cost elements do we need to consider\nwhen comparing TAVR and surgical AVR? So the main stay treatment,\nopen chest surgery.",
    "start": "1739490",
    "end": "1747260"
  },
  {
    "text": "We need to consider, for example,\nthe number of intensive care days that are required after one\nversus the other procedure.",
    "start": "1747260",
    "end": "1754190"
  },
  {
    "text": "We need to consider length of stay. And we need to consider certainly\nthe cost of the wealth,",
    "start": "1754190",
    "end": "1761169"
  },
  {
    "text": "a transcatheter aortic heart valve\nactually costs around $30,000",
    "start": "1761170",
    "end": "1766688"
  },
  {
    "text": "in the United States versus\nmaybe 6,000 for a surgical belt.",
    "start": "1766688",
    "end": "1771770"
  },
  {
    "text": "And you can imagine how that\nfactors into the cost equation and the cost difference equation.",
    "start": "1771770",
    "end": "1777410"
  },
  {
    "text": "So what clinical data are needed\nto support cost calculations? As I mentioned earlier on\nthe effectiveness side,",
    "start": "1778760",
    "end": "1784388"
  },
  {
    "text": "there are parameters like stroke rates,\nand heart attack rates that might also be influenced by the use\nof this different technology.",
    "start": "1784388",
    "end": "1791860"
  },
  {
    "text": "And certainly we want to capture those\nalso on the cost side as the treatment",
    "start": "1791860",
    "end": "1797530"
  },
  {
    "text": "of this drug has immediate cost\nimplications and long term implications.",
    "start": "1797530",
    "end": "1801380"
  },
  {
    "text": "More data sources could be used\nto support a cost assessment where we could do a micro-costing\napproach during the trial.",
    "start": "1802580",
    "end": "1809565"
  },
  {
    "text": "That there's also extensive literature or publication based data available that\ndiscuss the cost of a stroke treatment or",
    "start": "1809566",
    "end": "1818010"
  },
  {
    "text": "to discuss the cost of an ICU aid,\nintensive care aid. But there are a number of sources we\ncan rely on when performing these",
    "start": "1818010",
    "end": "1826220"
  },
  {
    "text": "health economic value assessments. My therapy difference is between\nthat groups of patients, absolutely.",
    "start": "1826220",
    "end": "1832900"
  },
  {
    "text": "So again it shows that we need\nto be aware of the specific target population that we're evaluating,\nnot only from a regulatory perspective but",
    "start": "1832900",
    "end": "1842370"
  },
  {
    "text": "also from the health economic perspective. And you think of high risk patient or\nextreme risk patients for example,",
    "start": "1842370",
    "end": "1847895"
  },
  {
    "text": "versus intermediate risk patients,\nthe safety profile and the health economic profile\ncould look very different.",
    "start": "1847895",
    "end": "1855740"
  },
  {
    "text": "And you should also appreciate that\nwhen going back to the benefits outweighing the risks equation, right.",
    "start": "1855740",
    "end": "1861610"
  },
  {
    "text": "Or the scale here that we saw earlier\nthat certainly the risks in patients that",
    "start": "1861610",
    "end": "1867017"
  },
  {
    "text": "are at extreme risk are much different\nthan patients at intermediate risk.",
    "start": "1867017",
    "end": "1872359"
  },
  {
    "text": "Right, so keep that in mind.",
    "start": "1872359",
    "end": "1874151"
  },
  {
    "start": "1876000",
    "end": "1956000"
  },
  {
    "text": "If you're interested in reading more\nabout the health-economic evaluation of a transcatheter aortic heart valve,",
    "start": "1877543",
    "end": "1883767"
  },
  {
    "text": "there's an interesting\nstudy by Reynolds and colleagues that was published last year\nand they give you the reference down here.",
    "start": "1883767",
    "end": "1890570"
  },
  {
    "text": "But it shows what we just looked\nat this plane of cost and effect, and the likelihood that",
    "start": "1890570",
    "end": "1897020"
  },
  {
    "text": "the technology actually would be\ncost-effective when considering a threshold of 50 to $150,000 per college\nsupply period in the United States.",
    "start": "1897020",
    "end": "1905430"
  },
  {
    "text": "And the conclusion of that study was even\nthough technology costs more from a health care system perspective,\nthe improved outcomes actually",
    "start": "1905430",
    "end": "1913830"
  },
  {
    "text": "lead to a very favorable\nhealth-economic profile, willingness to pay off the society as\nstated in the United States between 50 and",
    "start": "1915350",
    "end": "1923649"
  },
  {
    "text": "150,000 Means that this should be adopted,\neven if it's higher cost.",
    "start": "1923649",
    "end": "1928120"
  },
  {
    "text": "There are also a couple of\ninteresting regulatory documents. The pre-market approval PMA summary\nof the Transcatheter Heart Valve",
    "start": "1931980",
    "end": "1939930"
  },
  {
    "text": "device is available under\nthis link at the agency and you find all of the documentation\nof the clinical studies and",
    "start": "1939930",
    "end": "1947340"
  },
  {
    "text": "pre clinical studies that were performed,\nso it's very educational. Similarly as I mentioned\nthe cost effectiveness article.",
    "start": "1947340",
    "end": "1954559"
  },
  {
    "start": "1956000",
    "end": "2417000"
  },
  {
    "text": "So to briefly summarize without regulatory\napproval there's no market access The key",
    "start": "1957002",
    "end": "1962914"
  },
  {
    "text": "criteria for approval in the United States\nare safety and effectiveness.",
    "start": "1962915",
    "end": "1968720"
  },
  {
    "text": "We need to determine early on, how the product will be regulated because\nthat drives the regulatory requirement.",
    "start": "1968720",
    "end": "1975540"
  },
  {
    "text": "We also need to appreciate detailed\nrequirement with regards to clinical testing and so on for\neach of the FDA pathways.",
    "start": "1975540",
    "end": "1984460"
  },
  {
    "text": "And FDA online resources are available\nagain if you want to study further. We can also learn from published\ndocuments of prior approvals and",
    "start": "1984460",
    "end": "1992510"
  },
  {
    "text": "panel meetings that are published on\nthe FDA website, a trove of evidence and information that really is very helpful.",
    "start": "1992510",
    "end": "2000010"
  },
  {
    "text": "And as discussed and then a population\nappropriate comparative predicate endpoints can be gleaned\nfrom those publications.",
    "start": "2000010",
    "end": "2007375"
  },
  {
    "text": "QSR, good laboratory practices,\nand good manufacturing practices, as discussed, are additional\nimportant elements of regulation.",
    "start": "2009252",
    "end": "2018179"
  },
  {
    "text": "On the health economics side, we have\nseen that health economic evaluation",
    "start": "2020000",
    "end": "2025090"
  },
  {
    "text": "increasingly is a critical requirement. Any health care system that wants to make\nmeaningful decisions about the adoption of",
    "start": "2025090",
    "end": "2032930"
  },
  {
    "text": "devices and their reimbursement\nprice needs to evaluate the healthcare benefits and the patient\nbenefits and the cost of the technology.",
    "start": "2032930",
    "end": "2042340"
  },
  {
    "text": "And that means for us,\nfrom a innovator perspective, that we need to be aware\nof those requirements. We need to actually collect information\nduring the trial and during development,",
    "start": "2042340",
    "end": "2051800"
  },
  {
    "text": "already collecting evidence that we can\nuse to demonstrate the value proposition. We also need to appreciate what are the\nkey value drivers of a new therapy,",
    "start": "2051800",
    "end": "2060830"
  },
  {
    "text": "very early on in development. And we need to appreciate that it's\nnot only the episode of care or",
    "start": "2060830",
    "end": "2066879"
  },
  {
    "text": "episode of implantation, but the long-term implications and effects\nof the therapy that we need to consider.",
    "start": "2066880",
    "end": "2072780"
  },
  {
    "text": "Value is defined by incremental changes\nfrom current status quo, so we need to appreciate what are the current therapies,\nwhat are the outcomes, and the cost.",
    "start": "2072780",
    "end": "2080379"
  },
  {
    "text": "And, again, we have differences\nbetween individual countries. Useful resources for\nhealth economics are HTAs or",
    "start": "2080380",
    "end": "2087330"
  },
  {
    "text": "health technology assessment reports that\nare published and publicly available as well as cost effectiveness\nstudies in the published literature.",
    "start": "2087330",
    "end": "2094730"
  },
  {
    "text": "So, with that, I'd like to briefly\nsay a few sentences about 256, which studying this year actually\nhas lifted bioengineering course,",
    "start": "2096845",
    "end": "2106415"
  },
  {
    "text": "bio e256 tech assessment and\nregulation of medical devices. It's a course that is given Fridays,\n1:30 to 3:20, nine sessions total",
    "start": "2106415",
    "end": "2115855"
  },
  {
    "text": "available through SCDB Lectures include\nguest speakers from industry and the FDA.",
    "start": "2115855",
    "end": "2121210"
  },
  {
    "text": "And also, a hands on team based\nclass project investigating a real world medical technology report\nfrom the regulatory perspective but",
    "start": "2121210",
    "end": "2128680"
  },
  {
    "text": "also on the health-economic\nvalue perspective. And you can find details on\nthe website which is given here.",
    "start": "2128680",
    "end": "2135277"
  },
  {
    "text": "Thank you very much. >> Thank you very much that\nwas a great presentation. And now, I'd like to hand back over to so",
    "start": "2137922",
    "end": "2144099"
  },
  {
    "text": "he can answer some of the questions\nthat you've been sending through. >> Thank you Marsha.",
    "start": "2144100",
    "end": "2149450"
  },
  {
    "text": "Thank you for all of your questions. We did receive a couple of\nthem that are listed here. And let me just go into them step by step.",
    "start": "2149450",
    "end": "2156310"
  },
  {
    "text": "One of you asked about the designed\nthinking process or concepts and",
    "start": "2157650",
    "end": "2162950"
  },
  {
    "text": "how they have been used and\napplied in the medical technology field.",
    "start": "2162950",
    "end": "2168190"
  },
  {
    "text": "And some of you that are not familiar\nwith designed thinking, it's a process",
    "start": "2168190",
    "end": "2173240"
  },
  {
    "text": "that was defined at Stanford and\nat IDO Evaluating or using concepts of",
    "start": "2173240",
    "end": "2180130"
  },
  {
    "text": "use identification, by observation and\nthose contents have been implemented,",
    "start": "2180130",
    "end": "2186480"
  },
  {
    "text": "mainly in the process,\ntaught at the center, that mentioned earlier Her fellowship\nis offered that emphasizes",
    "start": "2186480",
    "end": "2195830"
  },
  {
    "text": "heavily the early phases of the process\nof medical technology innovation,",
    "start": "2195830",
    "end": "2201130"
  },
  {
    "text": "where we try to have the fellows spend\ntime in the actual clinical studying.",
    "start": "2201130",
    "end": "2206329"
  },
  {
    "text": "And observe processes, to identify needs,\nand then in a very careful manner and",
    "start": "2206330",
    "end": "2212400"
  },
  {
    "text": "process narrow the needs down into\nthe most important needs that then",
    "start": "2212400",
    "end": "2218359"
  },
  {
    "text": "lead to the next step which is actually\ninnovation or inventing technologies and then figuring concepts down to one\nfinal product or product idea.",
    "start": "2218360",
    "end": "2228560"
  },
  {
    "text": "So, the design thinking process is really, we think, very aptical with medical\ntechnology and has been used for",
    "start": "2228560",
    "end": "2235680"
  },
  {
    "text": "50 years in the prior designed program\nvery efficiently, and effectively.",
    "start": "2235680",
    "end": "2239630"
  },
  {
    "text": "But, how do you prove, next question, how do you prove value on something\nlike preventative medicine?",
    "start": "2240850",
    "end": "2245960"
  },
  {
    "text": "A very good question, and indeed there are\nimportant programs that are supported by",
    "start": "2247080",
    "end": "2252930"
  },
  {
    "text": "technology also where you try to avoid or\nimprove the long-term patients outcome for",
    "start": "2252930",
    "end": "2258000"
  },
  {
    "text": "things, for example,\nwith weight management and obesity. You can think of cardiac risk factors.",
    "start": "2258000",
    "end": "2263940"
  },
  {
    "text": "If you manage them effectively, you can\ninfluence the long-term outcome and the benefit of the technology.",
    "start": "2263940",
    "end": "2270660"
  },
  {
    "text": "Are evaluated prospectively and\nsometimes in modern day assessment. So, you try to appreciate how behavior and\ncertain parameters",
    "start": "2270660",
    "end": "2281099"
  },
  {
    "text": "like blood pressure or weight are affected\nwith the use of such program.",
    "start": "2281100",
    "end": "2286419"
  },
  {
    "text": "And then, you can project\nthe likely long term impact and evaluate whether it would be meaningful,\nboth in terms of outcome, but",
    "start": "2286419",
    "end": "2292860"
  },
  {
    "text": "also in terms of cost, so\na very good question and there are many technologies actually\nthat focus on the parantative field.",
    "start": "2292860",
    "end": "2299540"
  },
  {
    "text": "There's one question about transcarotid\nback replacement here I mentioned",
    "start": "2302170",
    "end": "2308630"
  },
  {
    "text": "the roughly $30,000 cost that is published\nin publications in the United States.",
    "start": "2308630",
    "end": "2313660"
  },
  {
    "text": "And the question is what is the price? There are some variations.",
    "start": "2314670",
    "end": "2319820"
  },
  {
    "text": "And again, just going back public domain\ninformation in European countries.",
    "start": "2319820",
    "end": "2327789"
  },
  {
    "text": "According to publications It's\nin the range of 20,000 Euros. Again, variation within those countries\nbut yes, there are global differences.",
    "start": "2327789",
    "end": "2336800"
  },
  {
    "text": "But we need to also keep in mind\nthat healthcare in general and healthcare systems costs are very\ndifferent in these other markets.",
    "start": "2336800",
    "end": "2344680"
  },
  {
    "text": "And certainly, pricing of technologies impacts the value\nproposition of the technology as well.",
    "start": "2344680",
    "end": "2352839"
  },
  {
    "text": "These are all very intertwined aspects. And we just look at\nthe next question here,",
    "start": "2352840",
    "end": "2359977"
  },
  {
    "text": "how will the changes in development of\nmedical device regulation in Europe and in Asia affect the development\nof innovative medical devices?",
    "start": "2359977",
    "end": "2368250"
  },
  {
    "text": "For a long time, Europe was seen, from a regulatory perspective, more\ninnovation, and that still is the case.",
    "start": "2368250",
    "end": "2376160"
  },
  {
    "text": "But there are some changes\nin regulation on the way,",
    "start": "2376160",
    "end": "2381770"
  },
  {
    "text": "currently need to be approved\nby the European Parliament, to be implemented, but\nespecially for high risk devices.",
    "start": "2381770",
    "end": "2389430"
  },
  {
    "text": "The requirements are now suppose to\nbe a little bit more stringent and also to the PMA evaluation\nin the United States.",
    "start": "2389430",
    "end": "2397540"
  },
  {
    "text": "In Asia there are changes,\nin Japan it was significant.",
    "start": "2398720",
    "end": "2403330"
  },
  {
    "text": "There were significant issues\nwith a review process in that it took a very long time. And you can imagine that very long review\ntime means also delayed patient exits.",
    "start": "2404650",
    "end": "2412700"
  },
  {
    "text": "And the Japanese had their authorities\nthat worked hard in improving",
    "start": "2412700",
    "end": "2417790"
  },
  {
    "start": "2417000",
    "end": "2611000"
  },
  {
    "text": "a more rapid review while maintaining\nhigh levels of safety and effectiveness. But certainly those factors of global\nregulatory systems also influence",
    "start": "2417790",
    "end": "2427802"
  },
  {
    "text": "companies' strategic decision-making\nabout initial markets to access and",
    "start": "2427802",
    "end": "2433829"
  },
  {
    "text": "gain clinical experiences with,\nand commercialize. And I think there's one more question\nhere about doctor regulations can be,",
    "start": "2433829",
    "end": "2441995"
  },
  {
    "text": "would I talk a little bit more\nabout doctor regulations. Certainly, when you look at\nthe technologies we've evaluated, or",
    "start": "2441996",
    "end": "2449391"
  },
  {
    "text": "looked at, early on,\ndeep brain stimulation, heavily driven by doctor right when\nyou think of an ECG machine, or",
    "start": "2449391",
    "end": "2456968"
  },
  {
    "text": "even this mammography device that we\nlooked at, software plays a big role.",
    "start": "2456968",
    "end": "2461993"
  },
  {
    "text": "And FDA has guidelines for software\nregulation, and for software testing, and for failure modes and effect analysis.",
    "start": "2461993",
    "end": "2469450"
  },
  {
    "text": "So they are a key cornerstone of the\nreview process, certainly not an easy one.",
    "start": "2469450",
    "end": "2476240"
  },
  {
    "text": "And I think their continued\nefforts to study better or develop better approaches to evaluate software and\ndetermine how much radiation and",
    "start": "2476240",
    "end": "2485530"
  },
  {
    "text": "testing do you need to do of doctor to\nmake sure that it's reliable enough.",
    "start": "2485530",
    "end": "2491200"
  },
  {
    "text": "Something that is not only limited\nto the health care industry, but also to other industries\nlike automotive and",
    "start": "2491200",
    "end": "2497040"
  },
  {
    "text": "aerospace where you face the same\nissues of software reliability.",
    "start": "2497040",
    "end": "2500560"
  },
  {
    "text": ">> I'll jump in with one that came in a\nlittle bit later, but start-up companies, is it critical to consult with the FDA\nahead of time to prepare for approval?",
    "start": "2502636",
    "end": "2511990"
  },
  {
    "text": "If so, how to establish the connections? Perhaps with your you might\nhave some experience with that.",
    "start": "2511990",
    "end": "2518400"
  },
  {
    "text": ">> So it is always a good idea to\nfirst use the published resources.",
    "start": "2518400",
    "end": "2523730"
  },
  {
    "text": "And I mentioned the FDA website\nwith a lot of useful information. So, once you've done with a company\nthe homework and evaluated as good as you",
    "start": "2523730",
    "end": "2532079"
  },
  {
    "text": "can the resources, I think it's always\na good idea to reach out to the agency and have an early dialogue.",
    "start": "2532080",
    "end": "2537809"
  },
  {
    "text": "But you increase\nthe likelihood of success for outcome if you have done your\nhomework internally beforehand.",
    "start": "2539390",
    "end": "2545250"
  },
  {
    "text": "It's also a center at the FDA that's\ncalled DICE, division for industry and",
    "start": "2545250",
    "end": "2550980"
  },
  {
    "text": "consumer education, which has a hotline\nand provides free advice to companies.",
    "start": "2550980",
    "end": "2556200"
  },
  {
    "text": "And so I think the first step,\nin terms of FDA interaction, aside from the typical regulatory review\nbranch, context and division context",
    "start": "2556200",
    "end": "2566970"
  },
  {
    "text": "is to make use of that free advice\nthrough the center, again it's D-I-C-E",
    "start": "2566970",
    "end": "2572281"
  },
  {
    "text": "at the agency and they provide\nwebinars and also a telephone hotline.",
    "start": "2572281",
    "end": "2577500"
  },
  {
    "text": "That might be a good first segue,\nespecially for small companies who experience\nthis process for the first time.",
    "start": "2577500",
    "end": "2582060"
  },
  {
    "text": ">> Great, well thank you again for\nthe talk, Jan, and also being able to give really\nhelpful details on today's questions.",
    "start": "2584230",
    "end": "2590240"
  },
  {
    "text": "Thank you everyone who sent them in. I'm afraid we didn't have a chance to get\nthrough all of them because of the time. But hopefully you found a lot that's\nuseful to take away from that.",
    "start": "2590240",
    "end": "2598530"
  },
  {
    "text": "And enjoy the rest of your day.",
    "start": "2598530",
    "end": "2599618"
  }
]